Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder
R. Zeifman, A. Wagner
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Key points | Argues that psychedelics may hold promise for targeting core BPD treatment targets and that research on incorporating psychedelics into BPD interventions is warranted, while noting safety concerns and the absence of existing studies in this population. |
Abstract
Abstract Borderline Personality Disorder (BPD) is a severe psychiatric disorder characterized by behavioral dysregulation, emotion dysregulation, disturbances in self-identity, and social functioning. Despite the existence of evidence-based psychotherapeutic interventions for BPD, these interventions have important limitations (e.g., limited treatment efficacy). Furthermore, little evidence exists for the efficaciousness of pharmacological interventions for BPD. Thus, a strong need for improving current interventions for BPD exists. Although research incorporating psychedelics within interventions for a wide range of psychiatric disorders has shown promise, research has not yet explored the utility of incorporating psychedelics within interventions for BPD. Therefore, this paper reviews the impact of psychedelics on treatment targets in interventions for BPD (i.e., behavioral dysregulation, emotion dysregulation, disturbances in self-identity, and social functioning), as well as purported overlapping mechanisms of change between interventions for BPD and psychedelics (i.e., emotion dysregulation, mindfulness, and self-compassion). Finally, safety concerns, clinical recommendations, and proposed next research steps related to the administration of psychedelics to individuals with BPD are discussed. This paper aims to explore the case for conducting research on, and the potential clinical utility surrounding, incorporating psychedelics within interventions for BPD.
Citations in the library
Cited by 49
- The Therapeutic Potential of Psilocybin Molecules May 15, 2021
- Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression Frontiers in Pharmacology March 31, 2022
- Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Frontiers in Psychiatry February 21, 2020
- Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders February 1, 2023
- Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation Frontiers in Psychiatry August 7, 2020
and 44 more in the library
Cites 91
- Assessment of Mindfulness by Self-Report Assessment September 1, 2004
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 86 more in the library